14
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Growth factor receptors as targets for drug development: monoclonals beat kinase inhibitors to market, but are they better drugs?

Pages 487-489 | Published online: 25 Feb 2005

Bibliography

  • SALOMON DS, BRANDT R, CIARDIELLO F, NORMANNO N: Epidermal growth factor-related peptides and their re-ceptors in human malignancies. Grit. Rev. Oncol/Hema-tol. (1995) 19:183–232.
  • SLAMON D, LEYLAND-JONES B, SHAK S et al: Addition of herceptinTM (humanized anti-HER2 antibody) to first line chemotherapy for HERZ overexpressing meta-static breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational con-trolled phase III trial. Proceedings of the Amen can Society of Clinical Oncology (1998). Abstract 377.
  • PAWSON T: Protein modules and signalling networks. Nature (1995) 373:573–580.
  • BASELGA J, MENDELSOHN J: Receptor blockade with monoclonal antibodies as anti-cancer therapy. Phar-macol. Therap. (1994) 64(1):127–154.
  • LUETTEKE NC, PHILLIPS HK, QIU TH et al.: The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. (1994) 8:399–413.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.